Unlocking the potential of bispecific ADCs for targeted cancer therapy  

作　　者：Hongye Zeng Wenjing Ning Xue Liu Wenxin Luo Ningshao Xia 

机构地区：[1]State Key Laboratory of Vaccines for Infectious Diseases,Xiang An Biomedicine Laboratory,School of Public Health,Xiamen University,Xiamen,361102,China [2]National Institute of Diagnostics and Vaccine Development in Infectious Diseases,State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Innovation Platform for Industry-Education Integration in Vaccine Research,the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences,Xiamen University,Xiamen,361102,China

出　　处：《Frontiers of Medicine》2024年第4期597-621,共25页医学前沿（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.32070940 and 81991491);China Postdoctoral Science Foundation(No.2021M700115);Postdoctoral Innovation Talents Support Program(No.BX20220189);CAMS Innovation Fund for Medical Sciences(No.2019RU022);Fundamental Research Funds for the Central Universities(No.20720220006).

摘　　要：Antibody–drug conjugates(ADCs)are biologically targeted drugs composed of antibodies and cytotoxic drugs connected by linkers.These innovative compounds enable precise drug delivery to tumor cells,minimizing harm to normal tissues and offering excellent prospects for cancer treatment.However,monoclonal antibody-based ADCs still present challenges,especially in terms of balancing efficacy and safety.Bispecific antibodies are alternatives to monoclonal antibodies and exhibit superior internalization and selectivity,producing ADCs with increased safety and therapeutic efficacy.In this review,we present available evidence and future prospects regarding the use of bispecific ADCs for cancer treatment,including a comprehensive overview of bispecific ADCs that are currently in clinical trials.We offer insights into the future development of bispecific ADCs to provide novel strategies for cancer treatment.

关 键 词：antibody-drug conjugate bispecific antibody bispecific ADC CANCER 

分 类 号：R730.5[医药卫生—肿瘤]